Novartis to Seek FDA Emergency Use Approval for New COVID-19 Therapy

Novartis said the drug’s so-called multi-specific protein-based domains ensure strong neutralization of the CCP virus, even in the face of mutations of the pathogen’s spike protein, while limiting the development of escape mutants.